FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1038-1044 October 19, 1995 Number 16 Next

Abstract PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Cytomegalovirus (CMV) disease in immunocompromised patients correlates with a deficiency of CD8+ cytotoxic T lymphocytes specific for CMV. We evaluated the safety and immunologic effects of immunotherapy with clones of these lymphocytes in recipients of allogeneic bone marrow transplants.

Methods Clones of CD8+ cytotoxic T cells specific for CMV proteins were isolated from the blood of bone marrow donors. Fourteen patients each received four intravenous infusions of these clones from their donors beginning 30 to 40 days after marrow transplantation. The reconstitution of cellular immunity against CMV was monitored before and during the period of infusions and for up to 12 weeks after the final infusion. The rearranged genes encoding the T-cell receptor served as markers in evaluating the persistence of the transferred T cells.

Results No toxic effects related to the infusions were observed. Cytotoxic T cells specific for CMV were reconstituted in all patients. In vitro measurements showed that cytotoxic activity against CMV was significantly increased (P<0.001) after the infusions in 11 patients who were deficient in such activity before therapy. The level of activity achieved after the infusions was similar to that measured in the donors. Analysis of rearranged T-cell–receptor genes in T cells obtained from two recipients indicated that the transferred clones persisted for at least 12 weeks. Cytotoxic-T-cell activity declined in patients deficient in CD4+ T-helper cells specific for CMV, suggesting that helper-T-cell function is needed for the persistence of transferred CD8+ T cells. Neither CMV viremia nor CMV disease developed in any of the 14 patients.

Conclusions The transfer of CMV-specific clones of CD8+ T cells derived from the bone marrow donor is a safe and effective way to reconstitute cellular immunity against CMV after allogeneic marrow transplantation.

Deficiencies in the response of class I HLA–restricted CD8+ cytotoxic T lymphocytes specific for CMV are important in the pathogenesis of CMV disease in immunocompromised recipients of allogeneic marrow transplants.^17,18,19 These patients receive a conditioning treatment that destroys their T cells, and they depend on the recovery of virus-specific T-cell immunity by in vivo proliferation of T cells derived from the donor marrow. During the first 100 days after allogeneic marrow transplantation, half the recipients are persistently deficient in CD8+ cytotoxic T lymphocytes specific for CMV. It is in this subgroup of patients that CMV disease occurs.¹⁹

The transfer of syngeneic (i.e., involving genetically identical donors and recipients), polyclonal CD8+ T cells from immune mice to immunosuppressed mice provided protection from a viral challenge. CD4+ T cells were not protective.^20,21 Similarly, in humans polyclonal populations of lymphocytes obtained from the peripheral blood of the donor have been used successfully to treat the Epstein–Barr virus (EBV) lymphoproliferative syndrome that can develop after allogeneic marrow transplantation. However, the transfer of these unselected lymphocytes also caused graft-versus-host disease (GVHD).²² Enrichment of the lymphocytes in cytotoxic T cells specific for EBV by in vitro culture before transfer appears to reduce the risk of GVHD.²³ A more definitive strategy to reduce the risk of GVHD from allogeneic lymphocytes would be to use T-cell clones with specificity for the antigens of the pathogen being treated. Clones of cytotoxic T lymphocytes specific for CMV can be isolated from normal CMV-seropositive subjects. The predominant specificity of these clones is directed against CMV structural proteins, such as the matrix proteins pp65 and pp150, which are presented for recognition by cytotoxic T lymphocytes before new virions are formed in infected cells.^24,25

A preliminary study of three patients established the feasibility of transferring clones of CD8+ cytotoxic T lymphocytes specific for CMV from the marrow donor to the marrow-transplant recipient.²⁶ We report the results of a phase 1 trial in which the safety and efficacy of adoptive T-cell therapy were examined.

Methods

Patients

Eighteen patients undergoing HLA-identical allogeneic marrow transplantation from a CMV-seropositive related donor at the Fred Hutchinson Cancer Research Center were enrolled in a study to evaluate adoptive immunotherapy with clones of CD8+ T cells specific for CMV, beginning 30 to 40 days after marrow transplantation. The study was approved by the institutional review board, and all patients gave informed consent. Four patients did not receive T-cell infusions: two died before day 30, and two became ineligible because of grade III organ toxicity. None of the patients received prophylactic therapy with ganciclovir or immune globulin. Table 1 shows the clinical characteristics of the 14 treated patients.

View this table: [in this window] [in a new window]   Table 1. Clinical Characteristics of 14 Recipients of Allogeneic Bone Marrow Transplants Who Underwent Adoptive Immunotherapy.

 
Generation and Characterization of the Clones

Polyclonal cytotoxic-T-lymphocyte cultures specific for CMV were established as described elsewhere.^24,27 Skin-biopsy specimens were obtained from each marrow donor to establish a line of fibroblasts for use as stimulator and target cells. Peripheral-blood mononuclear cells (PBMCs) were obtained from the donor and cultured with autologous fibroblasts infected with the AD169 strain of CMV. The culture medium for the T cells was RPMI, supplemented with 25 mmol of Hepes buffer per liter; 11 percent AB-positive, CMV-seronegative serum from normal blood donors; 4 mmol of l-glutamine per liter; 50 U of penicillin per milliliter; 50 µg of streptomycin per milliliter; and 2.5x10-⁵ mol of 2-mercaptoethanol per liter of solution. CD8+ T cells were cloned from the cultures by the limiting-dilution method after 7 to 14 days, depending on whether CMV-specific cytolytic activity was detected in the cultured cells.^24,27

Clones of CD8+ cytotoxic T lymphocytes specific for CMV were isolated by depleting the culture of CD4+ T cells with the use of flasks coated with anti-CD4+ monoclonal antibody (Applied Immune Sciences, Santa Clara, Calif.) and plating the CD8+ T cells in 96-well round-bottomed plates (0.3 to 0.8 cell per well) with 50,000 gamma-irradiated (30-Gy) autologous PBMCs (PBMC_ir), 10,000 gamma-irradiated (80-Gy) autologous EBV-transformed B lymphoblasts (LCL_ir) as feeder cells, and 25 to 50 U of interleukin-2 per milliliter. Anti-CD3 monoclonal antibody (30 ng per milliliter) or autologous CMV-infected fibroblasts (2000 per well) were added to stimulate the T cells.^24,27 The clones were transferred to larger wells or tissue-culture flasks, and their numbers were increased to more than 1 billion by cyclic stimulation at 10-to-12-day intervals with either autologous CMV-infected fibroblasts or anti-CD3 monoclonal antibody in cultures supplemented with PBMC_ir and LCL_ir, with interleukin-2 added on days 1, 5, and 8 after stimulation. The expression of CD3, CD4, and CD8 was determined with a fluorescence-activated cell sorter, and clones of CD3+CD8+CD4- cytotoxic T lymphocytes were selected for use in therapy.²⁷ The sterility of the cultures was confirmed before each infusion. T-cell clones from all 18 donors were successfully generated for the therapy.

Assay for Cytotoxicity

The clones were assayed for HLA-restricted cytolytic activity specific for CMV in a five-hour chromium-release assay.^17,19 The target cells were autologous and HLa class I–mismatched CMV-infected or mock-infected fibroblasts incubated for 48 hours with 100 U of recombinant interferon gamma (Boehringer–Mannheim, Indianapolis) per milliliter to increase the sensitivity of the assay.²⁸ Spontaneous release of chromium, maximal release, and the percentage of CMV-infected cells killed (specific lysis) were calculated as described elsewhere.^17,19,24 Cytotoxic-T-lymphocyte clones that lysed more than 30 percent of autologous CMV-infected target cells and less than 5 percent of control target cells with an effector:target ratio of 5:1 were used in therapy. Clones of CD8+ cytotoxic T lymphocytes specific for structural virion proteins were identified by their ability to lyse CMV-infected target cells in the presence of dactinomycin to prevent the expression of viral genes, and these clones were selected for use in therapy.²⁴

Treatment Regimen

The clones of CMV-specific cytotoxic T lymphocytes were administered to each marrow-transplant recipient intravenously over a 30-minute period through a Hickman catheter in four escalating doses (33 million, 100 million, 330 million, and 1 billion cells per square meter of body-surface area), each given one week apart. Starting the treatment more than 30 days after transplantation made it easier to distinguish toxic effects related to T-cell infusions from earlier toxic effects due to the conditioning chemotherapy.

Monitoring of Patients

The first three patients received each infusion of T cells in the hospital, where their vital signs and oxygen saturation were monitored before the infusion and 15, 30, 60, and 120 minutes after the start of the infusion. The remaining 11 patients were treated in the outpatient department and were monitored in the same way. Complete blood counts were obtained and liver function was evaluated one day after each infusion and three times weekly until day 100. Chest radiographs were obtained one day after each infusion, and physical examinations were performed weekly. GVHD was graded according to published criteria.²⁹

Immunologic Monitoring

PBMCs were collected before the start of the T-cell infusions, 2 days after each infusion, and 2, 4, 6, and 12 weeks after the completion of therapy. Short-term cultures were generated from the PBMCs and assayed for CMV-specific CD8+ cytotoxic-T-lymphocyte activity.¹⁷ The activity of CMV-specific CD4+ T-helper cells in the PBMCs was also assayed by plating 200,000 PBMCs in triplicate in 96-well round-bottomed plates with medium alone, CMV antigen, or phytohemagglutinin (5 µg per milliliter).¹⁷ The wells were pulsed with tritiated thymidine (1 µCi per well) for the final 16 hours of a 96-hour incubation; the cells were then collected for scintillation counting. The data on T-helper responses were transformed into a stimulation index, defined as the mean number of counts per minute (cpm) for cells exposed to CMV antigen divided by the mean number of counts per minute for cells exposed only to tissue-culture medium.

In Vivo Persistence of Adoptively Transferred CD8+ Clones

A reverse-transcriptase polymerase chain reaction (PCR) was used to identify the variable genes (V and V) of the T-cell receptor expressed by the infused cytotoxic-T-lymphocyte clones and by clones isolated from the patients after the infusions. RNA was isolated from the clones with a total-RNA separator kit (Clonetech, Palo Alto, Calif.), and 1 to 2 µg of total RNA was reverse-transcribed to first-strand complementary DNA (cDNA).³⁰ The segments of the V and V genes expressed in the cDNA samples prepared from each clone were determined with 25 5' V primers for 24 known major V families (Clonetech) and 31 5' V primers, with 3' primers derived from the respective constant (C and C) sequences.³¹

Virologic Monitoring

Shell-vial and conventional cultures of buffy coat, urine, and throat for CMV were monitored weekly until day 100.

Results

Safety of Adoptive Transfer of CMV-Specific Clones

No patient had significant changes in blood pressure, heart rate, temperature, or oxygen saturation during the T-cell infusions. One patient had a transient fever after the fourth infusion; another patient with a history of chills after transfusions had chills during infusions 2, 3, and 4. Blood-chemistry values, chest radiographs, and blood counts were unchanged in all the patients.

Before receiving the infusions, two patients had grade I GVHD, and five patients had grade II or III GVHD. The dose of the immunosuppressive agents was not increased in the first two patients, but prednisone (2 to 3 mg per kilogram of body weight per day) was given to all five with more severe GVHD and then tapered during or after the infusions, with no flare of GVHD. In three patients GVHD developed during or after the completion of T-cell therapy. GVHD of grade I or II appeared five days after the first infusion and six days after the third infusion in two of these patients. They received 1 to 1.5 mg of prednisone per kilogram per day, which was tapered over a period of two to three weeks; they tolerated subsequent infusions of higher doses of cells without recurrent GVHD. Grade II GVHD developed two weeks after the final infusion in the third patient. Four patients had no evidence of GVHD during the study.

Reconstitution of CMV-Specific Immunity

PBMCs were collected before and after the T-cell infusions in order to evaluate CMV-specific reactivity of cytotoxic T lymphocytes. Eleven of the 14 patients lacked CMV-specific cytotoxic T lymphocytes immediately before the first infusion of CMV-specific clones. In all 11 patients, such lymphocytes were detected two days after the first infusion of T cells (Table 2). These responses persisted and increased in magnitude after successive infusions to such a degree that the reactivity of cytotoxic T lymphocytes after the fourth infusion did not differ significantly from that of the marrow donors (P = 0.86) (Figure 1). In two patients (Patients 9 and 10), the reactivity of CMV-specific cytotoxic T lymphocytes appeared to recover to levels below those detected in the donors (Table 2), but this reflected high levels of nonspecific lysis against autologous mock-infected target cells, which obscured the detection of CMV-specific lysis. This nonspecific activity remained after the depletion of natural killer cells (data not shown).

View this table: [in this window] [in a new window]   Table 2. Reconstitution of Cytotoxic-T-Lymphocyte Responses in Recipients of Bone Marrow Transplants with Adoptive Immunotherapy.

 

View larger version (3K): [in this window] [in a new window]   Figure 1. Reconstitution of Responses of CMV-Specific Cytotoxic T Lymphocytes with Adoptive Immunotherapy in 11 Patients. PBMCs from the recipients were tested before the first infusion of T cells and two days after each infusion; PBMCs from the donors were also tested. Solid bars indicate CD8+ cytotoxic-T-cell activity specific for CMV, shown as the mean (±SD) difference in the percentage of infected cells killed (specific lysis) between autologous CMV-infected fibroblasts and mock-infected fibroblasts. Open bars indicate nonspecific lytic activity, shown as the mean difference in the percentage of specific lysis between class I MHC–mismatched allogeneic CMV-infected fibroblasts and mock-infected fibroblasts. The responses measured after the fourth infusion were significantly higher than those measured before the first infusion (P<0.001 by the paired t-test) and did not differ significantly from the responses in the healthy donors (P = 0.86 by the paired t-test).

 
All 14 patients had reconstituted CMV-specific cytotoxic T lymphocytes by days 42 to 49 after marrow transplantation, whereas in previous studies of patients who did not receive adoptive immunotherapy, more than half were deficient in such responses at day 50.^17,19 Moreover, the recovery of endogenous cytotoxic T lymphocytes specific for CMV required the presence of CD4+ CMV-specific T-helper cells,^17,19 whereas Patients 1 through 9 had reconstituted cytotoxic T lymphocytes specific for CMV in the absence of detectable CMV-specific CD4+ helper t cells (mean stimulation index after the fourth infusion, 1.4; range, 0.2 to 1.9). The mean stimulation index after the fourth infusion in the five patients in whom these helper cells recovered was 4.1 (range, 2.6 to 6.2).

High doses of immunosuppressive therapy for severe GVHD may affect the survival, the activity, or both of infused cytotoxic T lymphocytes. Nine patients with GVHD received 1 to 3 mg of prednisone per kilogram per day in addition to cyclosporine or tacrolimus (FK 506). In six of these patients, including five who had deficient responses of helper T cells, the magnitude of the reconstitution of cytotoxic-T-lymphocyte responses was equal to or greater than that of the donors. Nonspecific cytolytic activity obscured the responses of cytotoxic T lymphocytes in two patients (Patients 9 and 10); in one patient (Patient 8), who was receiving 3 mg of prednisone per kilogram per day to treat grade III GVHD, the response of CMV-specific cytotoxic T lymphocytes after therapy was less than that of the marrow donor.

Persistence of Transferred CD8+ Clones

All the patients maintained cytotoxic-T-lymphocyte responses specific for CMV for at least eight weeks after the completion of T-cell therapy (Figure 2A, Figure 2B, Figure 2C, and Figure 2D). We used rearranged V and V genes for the T-cell receptor as molecular markers to evaluate the survival of the transferred clones in two patients (Patients 3 and 7) who received only one or two clones of cytotoxic T lymphocytes in each infusion (Table 3). The six clones recovered at each point up to 12 weeks after the treatment of Patient 7 expressed V and V T-cell–receptor genes that were identical to those of the infused clones; similar results were obtained for Patient 3 (Table 3). Sequencing of PCR products from representative clones (sequenced through the VJ [variable joining ] and VDJ [variable diversity joining ] regions) confirmed that they were identical to the sequences in the infused clones. Two clones of cytotoxic T lymphocytes specific for CMV were isolated from a third patient (Patient 8), who was receiving high-dose prednisone (3 mg per kilogram per day), two weeks after the fourth infusion of T cells. The V and V genes expressed by these clones were identical to those expressed by two clones given in the fourth infusion (data not shown).

View larger version (10K): [in this window] [in a new window]   Figure 2. Persistence of CD8+ Cytotoxic-T-Lymphocyte Responses Specific for CMV in Patients 3 and 7, in Whom CD4+ T-Helper Responses Specific for CMV Were and Were Not Recovered, Respectively. Panels A and B show the results of an assay for CD8+ cytotoxic T lymphocytes for CMV in cell lines derived by stimulation of PBMCs with autologous CMV-infected fibroblasts. The target cells include CMV-infected (solid bars) and uninfected (shaded bars) autologous fibroblasts and CMV-infected class I HLA–mismatched allogeneic fibroblasts (open bars). Data are shown at an effector:target ratio of 10:1. Panels C and D show the responses of CD4+ T-helper cells obtained at intervals of up to 12 weeks after the final infusion, expressed as a stimulation index defined as the mean number of counts per minute for cells exposed to CMV antigen divided by the mean number of counts per minute of cells exposed to medium. A stimulation index greater than 2.0 indicates a positive lymphoproliferative response.17

 

View this table: [in this window] [in a new window]   Table 3. Va and Vb Genes Expressed by the T-Cell Clones Transferred from the Donors and by Representative Clones Recovered from Patients 3 and 7.

 
Since CD4+ helper T cells sustain host virus–specific responses of CD8+ cytotoxic T lymphocytes during chronic viral infection,^19,36 we analyzed whether the recovery of helper T cells specific for CMV influenced the in vivo persistence of adoptively transferred CD8+ cytotoxic T lymphocytes. The magnitude of the CMV-specific responses of cytotoxic T lymphocytes decreased with time in patients in whom there was no recovery of CD4+ T-helper responses specific for CMV (Figure 2A, Figure 2B, Figure 2C, and Figure 2D). By contrast, the recovery of a T-helper response after the infusions was associated with sustained or increased responses of cytotoxic T lymphocytes, suggesting that the recovery of adequate T-helper function may facilitate the maintenance of transferred CD8+ cytotoxic T lymphocytes (Figure 2A, Figure 2B, Figure 2C, and Figure 2D).

Virologic Monitoring

Patients were tested weekly for CMV in the urine, throat, or blood. Ganciclovir was administered to two patients with urinary CMV, according to the practice standard at the time of the study. CMV may be excreted in the urine in persons without deficient T-cell function.³⁷ In one patient with a CMV-positive throat culture before the T-cell infusions, the virus was cleared after the first infusion. The cultures in the remaining 11 patients were negative, and none of the 14 patients had CMV viremia or CMV disease.

Discussion

This study shows that adoptive immunotherapy with CD8+ T-cell clones can safely restore CMV-specific cytotoxic-T-lymphocyte responses in recipients of allogeneic bone marrow transplants. Fifty-six infusions of CMV-specific cytotoxic-T-lymphocyte clones were administered to 14 patients without any major toxic effects.

In other studies, donor PBMCs were transferred to marrow-transplant recipients to treat relapses of leukemia, but GVHD developed in 9 of 11 recipients (grade I in 6 and grade III in 3).³⁸ In the 14 patients we studied, immunotherapy with clones that were selected for their capacity to recognize CMV antigens presented in association with class I HLA molecules reduced the risk of GVHD. All the T-cell clones administered as therapy recognized structural virion proteins; further study of the clones given to seven patients identified the pp65 and pp150 proteins of CMV as the dominant target antigens (data not shown).^24,25

Several results support our conclusion that the reconstitution and persistence of cytotoxic-T-lymphocyte responses specific for CMV were due to the transfer of cytotoxic-T-lymphocyte clones from the donor. First, selective recovery of cytotoxic T lymphocytes specific for CMV in the absence of CMV-specific helper T cells was not observed in any of 56 patients previously evaluated who had not received adoptive immunotherapy,^17,19 but such recovery was observed in all 11 patients who lacked CD4+ T-helper responses in this study. Second, the infusion of increasing doses of cells resulted in an increased CMV-specific cytotoxic-T-lymphocyte response in the recipient. Finally, the persistence of the transferred clones was demonstrated in three patients when the rearranged T-cell V and V genes were used as molecular markers.

The infusion of T-cell clones in patients who required high-dose immunosuppressive therapy for severe GVHD restored cytotoxic-T-lymphocyte responses specific for CMV, but not always to the level present in the immunocompetent donors, suggesting that such patients may benefit from higher doses of T cells. Patients who had a progressive decline in the response of cytotoxic T lymphocytes did not recover CD4+ CMV-specific T-helper responses, suggesting that the concurrent transfer of CD4+ T-helper cells or the administration of interleukin-2 may have application.^36,39 A potential problem with the administration of interleukin-2 early after allogeneic marrow transplantation is that it may worsen GVHD.

The absence of CMV viremia and CMV disease in the 14 patients who received adoptive immunotherapy suggests that studies of the efficacy of this approach as prophylaxis against CMV infection are warranted.

Supported by a grant (CA18029) from the National Cancer Institute. Dr. Walter was supported by the U.S. Air Force. Dr. Riddell is the recipient of a Partridge Foundation Investigator Award from the Cancer Research Institute, and Dr. Gilbert is the recipient of a postdoctoral fellowship (DRG-065) from the Cancer Research Fund.

We are indebted to Mark Elliot and Kimberly Stankey for expert technical assistance; to the members of the nursing and physician staffs at the Fred Hutchinson Cancer Research Center, for their contribution to the care of these patients; and to Jennifer Michaels for assistance in the preparation of the manuscript.

Source Information

From the Fred Hutchinson Cancer Research Center (E.A.W., P.D.G., M.J.G., K.S.W., E.D.T., S.R.R.) and the Departments of Immunology (P.D.G., R.J.F.) and Medicine (P.D.G., E.D.T., S.R.R.), University of Washington, Seattle.

Address reprint requests to Dr. Riddell at the Fred Hutchinson Cancer Research Center, Mailstop M758, 1124 Columbia St., Seattle, WA 98104.

References

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-488. [Medline]
2. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 1994;83:2393-2398. 
3. Smith MA, Brennessel DJ. Cytomegalovirus. Infect Dis Clin North Am 1994;8:427-438. [Medline]
4. Gallant JE, Moore RD, Richman DD. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-1227. [Medline]
5. Wiens M, Lefebre B, Blumhardt G, Schmidt CA, Lohmann R, Neuhaus P. Incidence and therapy of cytomegalovirus disease after liver transplantation. Transplant Proc 1993;25:1985-1986. [Medline]
6. Farrugia E, Schwab TR. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 1992;67:879-890. [Medline]
7. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006-1010. [Abstract]
8. Miller WJ, McCullough J, Balfour HH Jr, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991;7:227-234. [Medline]
9. Zaia JA. Cytomegalovirus infection. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Cambridge, Mass.: Blackwell Science, 1994:376-403.
10. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78:246-250. [Free Full Text]
11. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601-1607. [Abstract]
12. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991;324:1005-1011. [Abstract]
13. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109:783-788.
14. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988;109:777-782.
15. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-178. [Free Full Text]
16. Boeckh M, Gooley T, Goodrich J, Sullivan K, Bowden RA. Increased incidence of late cytomegalovirus disease in patients who received ganciclovir prophylaxis after allogeneic marrow transplantation. In: Abstracts of the Eighth International Symposium on Infections in the Immunocompromised Host, Davos, Switzerland, June 19–22, 1994. Comstock, Mich.: Immunocompromised Host Society, 1994. abstract.
17. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-1979. [Free Full Text]
18. Quinnan GV Jr, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982;307:7-13. [Abstract]
19. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-1380. [Free Full Text]
20. Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UH. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 1987;61:3102-3108. [Free Full Text]
21. Reddehase MJ, Weiland F, Munch K, Jonjic S, Luske A, Koszinowski UH. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 1985;55:264-273. [Free Full Text]
22. Papadopoulos ED, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191. [Free Full Text]
23. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13. [CrossRef][Medline]
24. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991;146:2795-2804. [Abstract]
25. McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103-110. [Medline]
26. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241. [Free Full Text]
27. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990;128:189-201. [CrossRef][Medline]
28. Laubscher A, Bluestein HG, Spector SA, Zvaifler NJ. Generation of human cytomegalovirus-specific cytotoxic T-lymphocytes in a short-term culture. J Immunol Methods 1988;110:69-77. [CrossRef][Medline]
29. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975;292:832-843. [Medline]
30. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory, 1989.
31. Genev'ee C, Diu A, Nierat J, et al. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol 1992;22:1261-1269. [Medline]
32. Casanova JL, Romero P, Widmann C, Kourilsky P, Maryanski JL. T cell receptor genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a plasmodium berghei nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire. J Exp Med 1991;174:1371-1383. [Free Full Text]
33. Malissen M, Trucy J, Letourneur R, et al. A T cell clone expresses two T cell receptor alpha genes but uses one alpha beta heterodimer for allorecognition and self MHC-restricted antigen recognition. Cell 1988;55:49-59. [CrossRef][Medline]
34. Padovan E, Casorati G, Dellabona P, Meyer S, Brockhaus M, Lanzavecchia A. Expression of T cell receptor alpha chains: dual receptor T cells. Science 1993;262:422-424. [Free Full Text]
35. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-5467. [Free Full Text]
36. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68:8056-8063. [Free Full Text]
37. Alford CA, Stagno S, Pass RF. Natural history of perinatal cytomegaloviral infection. In: Elliot K, ed. Perinatal infections. Amsterdam: Excerpta Medica, 1980:125-47.
38. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-106. [Free Full Text]
39. Reddehase MJ, Mutter W, Koszinowski UH. In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med 1987;165:650-656. [Free Full Text]

Abstract PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

Anticytomegalovirus T-Cell Clones
Locatelli F., Maccario R., Gerna G., Walter E. A., Greenberg P. D., Riddell S. R.
Extract | Full Text  
N Engl J Med 1996; 334:601, Feb 29, 1996. Correspondence

This article has been cited by other articles:

• Zhou, W., Longmate, J., Lacey, S. F., Palmer, J. M., Gallez-Hawkins, G., Thao, L., Spielberger, R., Nakamura, R., Forman, S. J., Zaia, J. A., Diamond, D. J. (2009). Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 113: 6465-6476 [Abstract] [Full Text]  
• Boeckh, M., Ljungman, P. (2009). How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113: 5711-5719 [Abstract] [Full Text]  
• Zaia, J. A., Li, X., Franck, A. E., Wu, X., Thao, L., Gallez-Hawkins, G. (2009). Biologic and Immunologic Effects of Knockout of Human Cytomegalovirus pp65 Nuclear Localization Signal. CVI 16: 935-943 [Abstract] [Full Text]  
• van Loenen, M. M., Hagedoorn, R. S., Kester, M. G.D., Hoogeboom, M., Willemze, R., Falkenburg, J.H. F., Heemskerk, M. H.M. (2009). Kinetic Preservation of Dual Specificity of Coprogrammed Minor Histocompatibility Antigen-Reactive Virus-Specific T Cells. Cancer Res. 69: 2034-2041 [Abstract] [Full Text]  
• Crough, T., Khanna, R. (2009). Immunobiology of Human Cytomegalovirus: from Bench to Bedside. Clin. Microbiol. Rev. 22: 76-98 [Abstract] [Full Text]  
• Joshi, A., Tang, J., Kuzma, M., Wagner, J., Mookerjee, B., Filicko, J., Carabasi, M., Flomenberg, N., Flomenberg, P. (2009). Adenovirus DNA polymerase is recognized by human CD8+ T cells. J. Gen. Virol. 90: 84-94 [Abstract] [Full Text]  
• Mackensen, A. (2009). Adoptive Transfer of Tumor Antigen-specific CD8+ T-cells to Patients with Melanoma: Strategies to Improve Therapeutic Efficacy. Am Soc Clin Oncol Ed Book 2009: 521-524 [Abstract] [Full Text]  
• Schroer, J., Shenk, T. (2008). Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 105: 19468-19473 [Abstract] [Full Text]  
• Micklethwaite, K. P., Clancy, L., Sandher, U., Hansen, A. M., Blyth, E., Antonenas, V., Sartor, M. M., Bradstock, K. F., Gottlieb, D. J. (2008). Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 112: 3974-3981 [Abstract] [Full Text]  
• Baron, M., Davignon, J.-L. (2008). Inhibition of IFN-{gamma}-Induced STAT1 Tyrosine Phosphorylation by Human CMV Is Mediated by SHP2. J. Immunol. 181: 5530-5536 [Abstract] [Full Text]  
• Walton, S. M., Wyrsch, P., Munks, M. W., Zimmermann, A., Hengel, H., Hill, A. B., Oxenius, A. (2008). The Dynamics of Mouse Cytomegalovirus-Specific CD4 T Cell Responses during Acute and Latent Infection. J. Immunol. 181: 1128-1134 [Abstract] [Full Text]  
• Truong, P., McGavern, D. B. (2008). A Novel Virus Carrier State to Evaluate Immunotherapeutic Regimens: Regulatory T Cells Modulate the Pathogenicity of Antiviral Memory Cells. J. Immunol. 181: 1161-1169 [Abstract] [Full Text]  
• Holtappels, R., Simon, C. O., Munks, M. W., Thomas, D., Deegen, P., Kuhnapfel, B., Daubner, T., Emde, S. F., Podlech, J., Grzimek, N. K. A., Oehrlein-Karpi, S. A., Hill, A. B., Reddehase, M. J. (2008). Subdominant CD8 T-Cell Epitopes Account for Protection against Cytomegalovirus Independent of Immunodomination. J. Virol. 82: 5781-5796 [Abstract] [Full Text]  
• Sebestyen, Z., Schooten, E., Sals, T., Zaldivar, I., San Jose, E., Alarcon, B., Bobisse, S., Rosato, A., Szollosi, J., Gratama, J. W., Willemsen, R. A., Debets, R. (2008). Human TCR That Incorporate CD3{zeta} Induce Highly Preferred Pairing between TCR{alpha} and {beta} Chains following Gene Transfer. J. Immunol. 180: 7736-7746 [Abstract] [Full Text]  
• Robbins, P. F., Li, Y. F., El-Gamil, M., Zhao, Y., Wargo, J. A., Zheng, Z., Xu, H., Morgan, R. A., Feldman, S. A., Johnson, L. A., Bennett, A. D., Dunn, S. M., Mahon, T. M., Jakobsen, B. K., Rosenberg, S. A. (2008). Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions. J. Immunol. 180: 6116-6131 [Abstract] [Full Text]  
• Rolle, C. E., Carrio, R., Malek, T. R. (2008). Modeling the CD8+ T Effector to Memory Transition in Adoptive T-Cell Antitumor Immunotherapy. Cancer Res. 68: 2984-2992 [Abstract] [Full Text]  
• Jorritsma, A., Bins, A. D., Schumacher, T. N.M., Haanen, J. B.A.G. (2008). Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer. Cancer Res. 68: 2455-2462 [Abstract] [Full Text]  
• Li, H., Chien, P. C. Jr., Tuen, M., Visciano, M. L., Cohen, S., Blais, S., Xu, C.-F., Zhang, H.-T., Hioe, C. E. (2008). Identification of an N-Linked Glycosylation in the C4 Region of HIV-1 Envelope gp120 That Is Critical for Recognition of Neighboring CD4 T Cell Epitopes. J. Immunol. 180: 4011-4021 [Abstract] [Full Text]  
• Nguyen, V. H., Shashidhar, S., Chang, D. S., Ho, L., Kambham, N., Bachmann, M., Brown, J. M., Negrin, R. S. (2008). The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 111: 945-953 [Abstract] [Full Text]  
• Leen, A. M., Christin, A., Khalil, M., Weiss, H., Gee, A. P., Brenner, M. K., Heslop, H. E., Rooney, C. M., Bollard, C. M. (2008). Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy. J. Virol. 82: 546-554 [Abstract] [Full Text]  
• Price, D. A., Bitmansour, A. D., Edgar, J. B., Walker, J. M., Axthelm, M. K., Douek, D. C., Picker, L. J. (2008). Induction and Evolution of Cytomegalovirus-Specific CD4+ T Cell Clonotypes in Rhesus Macaques. J. Immunol. 180: 269-280 [Abstract] [Full Text]  
• Klenovsek, K., Weisel, F., Schneider, A., Appelt, U., Jonjic, S., Messerle, M., Bradel-Tretheway, B., Winkler, T. H., Mach, M. (2007). Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110: 3472-3479 [Abstract] [Full Text]  
• Zhang, H., Snyder, K. M., Suhoski, M. M., Maus, M. V., Kapoor, V., June, C. H., Mackall, C. L. (2007). 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy. J. Immunol. 179: 4910-4918 [Abstract] [Full Text]  
• Delmas, S., Brousset, P., Clement, D., Le Roy, E., Davignon, J.-L. (2007). Anti-IE1 CD4+ T-cell clones kill peptide-pulsed, but not human cytomegalovirus-infected, target cells. J. Gen. Virol. 88: 2441-2449 [Abstract] [Full Text]  
• Yang, W, Beaudoin, E., Lu, L, Du Pasquier, R., Kuroda, M., Willemsen, R., Koralnik, I., Junghans, R. (2007). Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). Int Immunol 19: 1083-1093 [Abstract] [Full Text]  
• Humphreys, I. R., Loewendorf, A., de Trez, C., Schneider, K., Benedict, C. A., Munks, M. W., Ware, C. F., Croft, M. (2007). OX40 Costimulation Promotes Persistence of Cytomegalovirus-Specific CD8 T Cells: A CD4-Dependent Mechanism. J. Immunol. 179: 2195-2202 [Abstract] [Full Text]  
• Brennan, R. M., Miles, J. J., Silins, S. L., Bell, M. J., Burrows, J. M., Burrows, S. R. (2007). Predictable {alpha}{beta} T-Cell Receptor Selection toward an HLA-B*3501-Restricted Human Cytomegalovirus Epitope. J. Virol. 81: 7269-7273 [Abstract] [Full Text]  
• Reap, E. A., Dryga, S. A., Morris, J., Rivers, B., Norberg, P. K., Olmsted, R. A., Chulay, J. D. (2007). Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB Proteins. CVI 14: 748-755 [Abstract] [Full Text]  
• Miles, D. J. C., van der Sande, M., Jeffries, D., Kaye, S., Ismaili, J., Ojuola, O., Sanneh, M., Touray, E. S., Waight, P., Rowland-Jones, S., Whittle, H., Marchant, A. (2007). Cytomegalovirus Infection in Gambian Infants Leads to Profound CD8 T-Cell Differentiation. J. Virol. 81: 5766-5776 [Abstract] [Full Text]  
• Besold, K., Frankenberg, N., Pepperl-Klindworth, S., Kuball, J., Theobald, M., Hahn, G., Plachter, B. (2007). Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. J. Gen. Virol. 88: 1429-1439 [Abstract] [Full Text]  
• Charo, J., Robbins, P. F. (2007). Contrasting effects of FLIPL overexpression in human T cells on activation-induced cell death and cytokine production. J. Leukoc. Biol. 81: 1297-1302 [Abstract] [Full Text]  
• Khan, N., Best, D., Bruton, R., Nayak, L., Rickinson, A. B., Moss, P. A. H. (2007). T Cell Recognition Patterns of Immunodominant Cytomegalovirus Antigens in Primary and Persistent Infection. J. Immunol. 178: 4455-4465 [Abstract] [Full Text]  
• Wils, E.-J., Braakman, E., Verjans, G. M. G. M., Rombouts, E. J. C., Broers, A. E. C., Niesters, H. G. M., Wagemaker, G., Staal, F. J. T., Lowenberg, B., Spits, H., Cornelissen, J. J. (2007). Flt3 Ligand Expands Lymphoid Progenitors Prior to Recovery of Thymopoiesis and Accelerates T Cell Reconstitution after Bone Marrow Transplantation. J. Immunol. 178: 3551-3557 [Abstract] [Full Text]  
• Yue, Y., Kaur, A., Eberhardt, M. K., Kassis, N., Zhou, S. S., Tarantal, A. F., Barry, P. A. (2007). Immunogenicity and Protective Efficacy of DNA Vaccines Expressing Rhesus Cytomegalovirus Glycoprotein B, Phosphoprotein 65-2, and Viral Interleukin-10 in Rhesus Macaques. J. Virol. 81: 1095-1109 [Abstract] [Full Text]  
• Younes, S.-A., Trautmann, L., Yassine-Diab, B., Kalfayan, L. H., Kernaleguen, A.-E., Cameron, T. O., Boulassel, R., Stern, L. J., Routy, J.-P., Grossman, Z., Dumont, A. R., Sekaly, R.-P. (2007). The Duration of Exposure to HIV Modulates the Breadth and the Magnitude of HIV-Specific Memory CD4+ T Cells. J. Immunol. 178: 788-797 [Abstract] [Full Text]  
• Casazza, J. P., Betts, M. R., Price, D. A., Precopio, M. L., Ruff, L. E., Brenchley, J. M., Hill, B. J., Roederer, M., Douek, D. C., Koup, R. A. (2006). Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. JEM 203: 2865-2877 [Abstract] [Full Text]  
• Heemskerk, B., van Vreeswijk, T., Veltrop-Duits, L. A., Sombroek, C. C., Franken, K., Verhoosel, R. M., Hiemstra, P. S., van Leeuwen, D., Ressing, M. E., Toes, R. E. M., van Tol, M. J. D., Schilham, M. W. (2006). Adenovirus-Specific CD4+ T Cell Clones Recognizing Endogenous Antigen Inhibit Viral Replication In Vitro through Cognate Interaction. J. Immunol. 177: 8851-8859 [Abstract] [Full Text]  
• Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., Andreesen, R. (2006). Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma. JCO 24: 5060-5069 [Abstract] [Full Text]  
• Haveman, L. M., Bierings, M., Legger, E., Klein, M. R., de Jager, W., Otten, H. G., Albani, S., Kuis, W., Sette, A., Prakken, B. J. (2006). Novel pan-DR-binding T cell epitopes of adenovirus induce pro-inflammatory cytokines and chemokines in healthy donors. Int Immunol 18: 1521-1529 [Abstract] [Full Text]  
• Tu, W., Potena, L., Stepick-Biek, P., Liu, L., Dionis, K. Y., Luikart, H., Fearon, W. F., Holmes, T. H., Chin, C., Cooke, J. P., Valantine, H. A., Mocarski, E. S., Lewis, D. B. (2006). T-Cell Immunity to Subclinical Cytomegalovirus Infection Reduces Cardiac Allograft Disease. Circulation 114: 1608-1615 [Abstract] [Full Text]  
• Kennedy, R., Celis, E. (2006). T Helper Lymphocytes Rescue CTL from Activation-Induced Cell Death.. J. Immunol. 177: 2862-2872 [Abstract] [Full Text]  
• Park, K.-D., Marti, L., Kurtzberg, J., Szabolcs, P. (2006). In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 108: 1770-1773 [Abstract] [Full Text]  
• Lilleri, D., Gerna, G., Fornara, C., Lozza, L., Maccario, R., Locatelli, F. (2006). Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108: 1406-1412 [Abstract] [Full Text]  
• Clemenceau, B., Congy-Jolivet, N., Gallot, G., Vivien, R., Gaschet, J., Thibault, G., Vie, H. (2006). Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood 107: 4669-4677 [Abstract] [Full Text]  
• Guma, M., Budt, M., Saez, A., Brckalo, T., Hengel, H., Angulo, A., Lopez-Botet, M. (2006). Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107: 3624-3631 [Abstract] [Full Text]  
• Yue, Y., Kaur, A., Zhou, S. S., Barry, P. A. (2006). Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).. J. Gen. Virol. 87: 777-787 [Abstract] [Full Text]  
• Serrano, L. M., Pfeiffer, T., Olivares, S., Numbenjapon, T., Bennitt, J., Kim, D., Smith, D., McNamara, G., Al-Kadhimi, Z., Rosenthal, J., Forman, S. J., Jensen, M. C., Cooper, L. J. N. (2006). Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 107: 2643-2652 [Abstract] [Full Text]  
• Okazaki, T., Pendleton, C. D., Sarobe, P., Thomas, E. K., Iyengar, S., Harro, C., Schwartz, D., Berzofsky, J. A. (2006). Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine. J. Immunol. 176: 3753-3759 [Abstract] [Full Text]  
• Beck, O., Topp, M. S., Koehl, U., Roilides, E., Simitsopoulou, M., Hanisch, M., Sarfati, J., Latge, J. P., Klingebiel, T., Einsele, H., Lehrnbecher, T. (2006). Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 107: 2562-2569 [Abstract] [Full Text]  
• Wang, Y. M., Zhang, G. Y., Wang, Y., Hu, M., Wu, H., Watson, D., Hori, S., Alexander, I. E., Harris, D. C.H., Alexander, S. I. (2006). Foxp3-Transduced Polyclonal Regulatory T Cells Protect against Chronic Renal Injury from Adriamycin. J. Am. Soc. Nephrol. 17: 697-706 [Abstract] [Full Text]  
• Shlobin, O. A., West, E. E., Lechtzin, N., Miller, S. M., Borja, M., Orens, J. B., Dropulic, L. K., McDyer, J. F. (2006). Persistent Cytomegalovirus-Specific Memory Responses in the Lung Allograft and Blood following Primary Infection in Lung Transplant Recipients. J. Immunol. 176: 2625-2634 [Abstract] [Full Text]  
• McGavern, D. B. (2006). Immunotherapeutic relief from persistent infections and amyloid disorders. Neurology 66: S59-S64 [Abstract] [Full Text]  
• Trgovcich, J., Cebulla, C., Zimmerman, P., Sedmak, D. D. (2006). Human Cytomegalovirus Protein pp71 Disrupts Major Histocompatibility Complex Class I Cell Surface Expression. J. Virol. 80: 951-963 [Abstract] [Full Text]  
• Perruccio, K., Tosti, A., Burchielli, E., Topini, F., Ruggeri, L., Carotti, A., Capanni, M., Urbani, E., Mancusi, A., Aversa, F., Martelli, M. F., Romani, L., Velardi, A. (2005). Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106: 4397-4406 [Abstract] [Full Text]  
• Delmas, S., Martin, L., Baron, M., Nelson, J. A., Streblow, D. N., Davignon, J.-L. (2005). Optimization of CD4+ T Lymphocyte Response to Human Cytomegalovirus Nuclear IE1 Protein through Modifications of Both Size and Cellular Localization. J. Immunol. 175: 6812-6819 [Abstract] [Full Text]  
• Maia, S., Haining, W. N., Ansen, S., Xia, Z., Armstrong, S. A., Seth, N. P., Ghia, P., den Boer, M. L., Pieters, R., Sallan, S. E., Nadler, L. M., Cardoso, A. A. (2005). Gene Expression Profiling Identifies BAX-{delta} as a Novel Tumor Antigen in Acute Lymphoblastic Leukemia. Cancer Res. 65: 10050-10058 [Abstract] [Full Text]  
• Trautmann, L., Rimbert, M., Echasserieau, K., Saulquin, X., Neveu, B., Dechanet, J., Cerundolo, V., Bonneville, M. (2005). Selection of T Cell Clones Expressing High-Affinity Public TCRs within Human Cytomegalovirus-Specific CD8 T Cell Responses. J. Immunol. 175: 6123-6132 [Abstract] [Full Text]  
• Piriou, E., van Dort, K., Nanlohy, N. M., van Oers, M. H. J., Miedema, F., van Baarle, D. (2005). Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 106: 3166-3174 [Abstract] [Full Text]  
• Hegde, N. R., Dunn, C., Lewinsohn, D. M., Jarvis, M. A., Nelson, J. A., Johnson, D. C. (2005). Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. JEM 202: 1109-1119 [Abstract] [Full Text]  
• Lang, K. S., Recher, M., Navarini, A. A., Freigang, S., Harris, N. L., van den Broek, M., Odermatt, B., Hengartner, H., Zinkernagel, R. M. (2005). Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology. J. Immunol. 175: 5524-5531 [Abstract] [Full Text]  
• Reuter, J. D., Wilson, J. H., Idoko, K. E, van den Pol, A. N. (2005). CD4+ T-Cell Reconstitution Reduces Cytomegalovirus in the Immunocompromised Brain. J. Virol. 79: 9527-9539 [Abstract] [Full Text]  
• Cobbold, M., Khan, N., Pourgheysari, B., Tauro, S., McDonald, D., Osman, H., Assenmacher, M., Billingham, L., Steward, C., Crawley, C., Olavarria, E., Goldman, J., Chakraverty, R., Mahendra, P., Craddock, C., Moss, P. A.H. (2005). Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. JEM 202: 379-386 [Abstract] [Full Text]  
• Piriou, E., Jansen, C. A., Dort, K. v., De Cuyper, I., Nanlohy, N. M., Lange, J. M. A., van Oers, M. H. J., Miedema, F., van Baarle, D. (2005). Reconstitution of EBV Latent but Not Lytic Antigen-Specific CD4+ and CD8+ T Cells after HIV Treatment with Highly Active Antiretroviral Therapy. J. Immunol. 175: 2010-2017 [Abstract] [Full Text]  
• Kutzler, M. A., Robinson, T. M., Chattergoon, M. A., Choo, D. K., Choo, A. Y., Choe, P. Y., Ramanathan, M. P., Parkinson, R., Kudchodkar, S., Tamura, Y., Sidhu, M., Roopchand, V., Kim, J. J., Pavlakis, G. N., Felber, B. K., Waldmann, T. A., Boyer, J. D., Weiner, D. B. (2005). Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help. J. Immunol. 175: 112-123 [Abstract] [Full Text]  
• Imai, C., Iwamoto, S., Campana, D. (2005). Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383 [Abstract] [Full Text]  
• Posnett, D. N., Engelhorn, M. E., Houghton, A. N. (2005). Antiviral T cell responses: phalanx or multipronged attack?. JEM 201: 1881-1884 [Abstract] [Full Text]  
• Chakraborty, R., Morel, A.-S., Sutton, J. K., Appay, V., Ripley, R. M., Dong, T., Rostron, T., Ogola, S., Palakudy, T., Musoke, R., D'Agostino, A., Ritter, M., Rowland-Jones, S. L. (2005). Correlates of Delayed Disease Progression in HIV-1-Infected Kenyan Children. J. Immunol. 174: 8191-8199 [Abstract] [Full Text]  
• Fujiwara, H., Melenhorst, J. J., El Ouriaghli, F., Kajigaya, S., Grube, M., Sconocchia, G., Rezvani, K., Price, D. A., Hensel, N. F., Douek, D. C., Barrett, A. J. (2005). In vitro Induction of Myeloid Leukemia-Specific CD4 and CD8 T Cells by CD40 Ligand - Activated B Cells Gene Modified to Express Primary Granule Proteins. Clin. Cancer Res. 11: 4495-4503 [Abstract] [Full Text]  
• Flynn, J. N., Pistello, M., Isola, P., Zaccaro, L., Del Santo, B., Ricci, E., Matteucci, D., Bendinelli, M. (2005). Adoptive Immunotherapy of Feline Immunodeficiency Virus with Autologous Ex Vivo-Stimulated Lymphoid Cells Modulates Virus and T-Cell Subsets in Blood. CVI 12: 736-745 [Abstract] [Full Text]  
• Straathof, K. C., Pule, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., Rooney, C. M. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood 105: 4247-4254 [Abstract] [Full Text]  
• Morris, E. C., Tsallios, A., Bendle, G. M., Xue, S.-a., Stauss, H. J. (2005). A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. USA 102: 7934-7939 [Abstract] [Full Text]  
• Pahl-Seibert, M.-F., Juelch, M., Podlech, J., Thomas, D., Deegen, P., Reddehase, M. J., Holtappels, R. (2005). Highly Protective In Vivo Function of Cytomegalovirus IE1 Epitope-Specific Memory CD8 T Cells Purified by T-Cell Receptor-Based Cell Sorting. J. Virol. 79: 5400-5413 [Abstract] [Full Text]  
• Zhao, Y., Zheng, Z., Robbins, P. F., Khong, H. T., Rosenberg, S. A., Morgan, R. A. (2005). Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines. J. Immunol. 174: 4415-4423 [Abstract] [Full Text]  
• Trivedi, D., Williams, R. Y., O'Reilly, R. J., Koehne, G. (2005). Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 105: 2793-2801 [Abstract] [Full Text]  
• Khan, N., Bruton, R., Taylor, G. S., Cobbold, M., Jones, T. R., Rickinson, A. B., Moss, P. A. H. (2005). Identification of Cytomegalovirus-Specific Cytotoxic T Lymphocytes In Vitro Is Greatly Enhanced by the Use of Recombinant Virus Lacking the US2 to US11 Region or Modified Vaccinia Virus Ankara Expressing Individual Viral Genes. J. Virol. 79: 2869-2879 [Abstract] [Full Text]  
• Charo, J., Finkelstein, S. E., Grewal, N., Restifo, N. P., Robbins, P. F., Rosenberg, S. A. (2005). Bcl-2 Overexpression Enhances Tumor-Specific T-Cell Survival. Cancer Res. 65: 2001-2008 [Abstract] [Full Text]  
• Roszkowski, J. J., Lyons, G. E., Kast, W. M., Yee, C., Van Besien, K., Nishimura, M. I. (2005). Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor. Cancer Res. 65: 1570-1576 [Abstract] [Full Text]  
• Cooper, L. J. N., Al-Kadhimi, Z., Serrano, L. M., Pfeiffer, T., Olivares, S., Castro, A., Chang, W.-C., Gonzalez, S., Smith, D., Forman, S. J., Jensen, M. C. (2005). Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 105: 1622-1631 [Abstract] [Full Text]  
• Springer, K. L., Chou, S., Li, S., Giller, R. H., Quinones, R., Shira, J. E., Weinberg, A. (2005). How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients. J. Clin. Microbiol. 43: 208-213 [Abstract] [Full Text]  
• Riddell, S. R. (2004). Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy. JEM 200: 1533-1537 [Abstract] [Full Text]  
• Khan, N., Hislop, A., Gudgeon, N., Cobbold, M., Khanna, R., Nayak, L., Rickinson, A. B., Moss, P. A. H. (2004). Herpesvirus-Specific CD8 T Cell Immunity in Old Age: Cytomegalovirus Impairs the Response to a Coresident EBV Infection. J. Immunol. 173: 7481-7489 [Abstract] [Full Text]  
• Uchida, N., Tsunoda, T., Wada, S., Furukawa, Y., Nakamura, Y., Tahara, H. (2004). Ring Finger Protein 43 as a New Target for Cancer Immunotherapy. Clin. Cancer Res. 10: 8577-8586 [Abstract] [Full Text]  
• Ochsenbein, A. F., Riddell, S. R., Brown, M., Corey, L., Baerlocher, G. M., Lansdorp, P. M., Greenberg, P. D. (2004). CD27 Expression Promotes Long-Term Survival of Functional Effector-Memory CD8+ Cytotoxic T Lymphocytes in HIV-infected Patients. JEM 200: 1407-1417 [Abstract] [Full Text]  
• Torikai, H., Akatsuka, Y., Miyazaki, M., Warren, E. H. III, Oba, T., Tsujimura, K., Motoyoshi, K., Morishima, Y., Kodera, Y., Kuzushima, K., Takahashi, T. (2004). A Novel HLA-A*3303-Restricted Minor Histocompatibility Antigen Encoded by an Unconventional Open Reading Frame of Human TMSB4Y Gene. J. Immunol. 173: 7046-7054 [Abstract] [Full Text]  
• Weekes, M. P., Wills, M. R., Sissons, J. G. P., Carmichael, A. J. (2004). Long-Term Stable Expanded Human CD4+ T Cell Clones Specific for Human Cytomegalovirus Are Distributed in Both CD45RAhigh and CD45ROhigh Populations. J. Immunol. 173: 5843-5851 [Abstract] [Full Text]  
• Chang, W. L. W., Baumgarth, N., Yu, D., Barry, P. A. (2004). Human Cytomegalovirus-Encoded Interleukin-10 Homolog Inhibits Maturation of Dendritic Cells and Alters Their Functionality. J. Virol. 78: 8720-8731 [Abstract] [Full Text]  
• Manley, T. J., Luy, L., Jones, T., Boeckh, M., Mutimer, H., Riddell, S. R. (2004). Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood 104: 1075-1082 [Abstract] [Full Text]  
• Wang, Z., La Rosa, C., Mekhoubad, S., Lacey, S. F., Villacres, M. C., Markel, S., Longmate, J., Ellenhorn, J. D. I., Siliciano, R. F., Buck, C., Britt, W. J., Diamond, D. J. (2004). Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104: 847-856 [Abstract] [Full Text]  
• Parkhurst, M. R., Riley, J. P., Igarashi, T., Li, Y., Robbins, P. F., Rosenberg, S. A. (2004). Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously Expressing Telomerase. Clin. Cancer Res. 10: 4688-4698 [Abstract] [Full Text]  
• Blattman, J. N., Greenberg, P. D. (2004). Cancer Immunotherapy: A Treatment for the Masses. Science 305: 200-205 [Abstract] [Full Text]  
• Kotloff, R. M., Ahya, V. N., Crawford, S. W. (2004). Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation. Am. J. Respir. Crit. Care Med. 170: 22-48 [Abstract] [Full Text]  
• Senechal, B., Boruchov, A. M., Reagan, J. L., Hart, D. N. J., Young, J. W. (2004). Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood 103: 4207-4215 [Abstract] [Full Text]  
• Huang, J., El-Gamil, M., Dudley, M. E., Li, Y. F., Rosenberg, S. A., Robbins, P. F. (2004). T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product. J. Immunol. 172: 6057-6064 [Abstract] [Full Text]  
• Li Pira, G., Bottone, L., Ivaldi, F., Pelizzoli, R., Del Galdo, F., Lozzi, L., Bracci, L., Loregian, A., Palu, G., De Palma, R., Einsele, H., Manca, F. (2004). Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution. Int Immunol 16: 635-642 [Abstract] [Full Text]  
• Rauser, G., Einsele, H., Sinzger, C., Wernet, D., Kuntz, G., Assenmacher, M., Campbell, J. D. M., Topp, M. S. (2004). Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 103: 3565-3572 [Abstract] [Full Text]  
• Verra, N. C. V., Jorritsma, A., Weijer, K., Ruizendaal, J. J., Voordouw, A., Weder, P., Hooijberg, E., Schumacher, T. N. M., Haanen, J. B. A. G., Spits, H., Luiten, R. M. (2004). Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice. Cancer Res. 64: 2153-2161 [Abstract] [Full Text]  
• Boeckh, M., Nichols, W. G. (2004). The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008 [Abstract] [Full Text]